Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024GlobeNewsWire • 02/22/24
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced MelanomaPRNewsWire • 02/20/24
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In MelanomaSeeking Alpha • 02/20/24
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common StockGlobeNewsWire • 02/20/24
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024GlobeNewsWire • 02/16/24
Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced MelanomaGlobeNewsWire • 02/16/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAPRNewsWire • 01/23/24
Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook PromisingSeeking Alpha • 01/21/24
Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA DateSeeking Alpha • 01/19/24